Management of inflammatory bowel disease (IBD) remains a clinical challenge in patients with active cancer. Observational data have shown that treatment modification is made for either IBD and/or cancer once the diagnosis of cancer is made in such patients. Impact of these changes on the course of IBD and/or cancer and the use of biologics for IBD management with concomitant chemotherapy for cancer is not studied. Our aim is to assess the safety of concomitant biologic use with chemotherapy in IBD patients with cancer and assess IBD disease course with cancer treatment.